The University of Münster is partner in a project of the research area "Healthcare-associated and Antibiotic-resistant bacteria", in which the lytic phage protein HY-133 is being investigated. The protein has proven to be very effective against methicillin-resistant Staphylococcus aureus bacteria in the nasal cavity. This promising compound is currently being investigated in preclinical studies to ensure safety in subsequent clinical trials in humans. Another project is located in the research area "Gastrointestinal Infections" and deals with new inhibitors against pathogens such as salmonella.
Scientists at the University of Münster are also involved in the development of new antibiotics against multi-resistant tuberculosis bacteria.